BAJAJ BROKING
Apollo Hospitals has launched Asia’s first dedicated cancer centre for women in New Delhi. The new facility focuses on the treatment and research of women-specific cancers. The centre aims to improve access, shorten treatment time, and provide specialised care with advanced oncology technologies.
Source: Apollo Hospital Press Release (NSE Exchange Filings) | Published on Sept 17, 2025
Disclaimer: This content has been published for informational purposes only. Bajaj Broking is not affiliated with, nor does it endorse or assume any responsibility for, the source material. Readers are advised to consult the original publication for complete and accurate context.
As quoted in the press release from Apollo Hospitals (NSE Exchange filings), the healthcare group has inaugurated Asia’s first cancer centre dedicated to women in New Delhi. The centre has been designed to provide specialised oncology services, focusing exclusively on cancers that affect women, such as breast, ovarian, cervical, and uterine cancers.
Also read: Mahindra Lifespaces to redevelop two Chembur societies worth ₹1,700 cr
Apollo Hospitals launched Asia’s first women’s cancer centre in New Delhi.
The centre focuses on breast, ovarian, cervical, and uterine cancers.
Advanced diagnostic and therapeutic technologies are integrated.
The aim is to provide comprehensive oncology care for women.
The facility is expected to improve early detection and survival rates.
Also read: Dr Reddy’s introduces tegoprazan, a new gastro drug in India market
The cancer centre has been developed as a standalone facility to address specific oncology needs. Apollo Hospitals emphasised the importance of tackling cancers that account for nearly half of all cancer cases among women in India. The centre brings together screening, diagnosis, surgery, radiotherapy, chemotherapy, and rehabilitation under one roof, ensuring seamless care. It will also use advanced oncology equipment and AI-based diagnostic tools to deliver personalised treatment.
In India, the most common cancer among women is breast cancer, which currently accounts for over 14% of the cases. Cervical cancer is the second most frequently reported cancer, with thousands of cases diagnosed each year. Ovarian and uterine cancers are also growing in prevalence, partly due to lifestyle changes and demographic shifts. The centre's philosophy addresses this challenge through the development of new approaches to early detection, genetic counselling, and advanced surgical techniques.
The centre aims to decrease patient wait times associated with oncology treatment by providing all services in one location. Integrated care allows patients to avoid adding wait times caused by transferring between different locations. This center is aligned with Apollo Hospitals vision to increase access to high quality and complex care across the country. The center will also engage in community outreach programs to promote prevention and ongoing screening for patients.
The new women-focused cancer centre in New Delhi is expected to draw patients from across Asia, positioning the city as a hub for specialised oncology care. The investment will create jobs in healthcare, research, and support services, while also encouraging collaboration and knowledge-sharing with regional healthcare systems. Greater private sector involvement in specialised care is likely to ease pressure on public hospitals and improve overall access.
Feature | Detail |
Facility type | Women’s Cancer Centre |
Location | New Delhi |
Focus areas | Breast, ovarian, cervical, and uterine cancers |
Services offered | Screening, diagnosis, treatment, rehabilitation |
Technology used | Advanced oncology and AI-based diagnostics |
On 16 September 2025 at 15:30 PM IST, the Apollo Hospitals share price on NSE was ₹6,845.20. The announcement was noted by the market, reflecting Apollo’s continued expansion in specialised healthcare. The price movement in the company’s shares shows that the launch was interpreted as a by-product of Apollo’s strategy to strengthen its oncology portfolio.
More broadly, the Apollo Hospitals share price may represent the long-term benefits of its investments in healthcare infrastructure, particularly since oncology services comprise a major portion of revenues in the healthcare sector. And the continued focus on women’s oncology demonstrates the company’s strategy to build differentiated healthcare experiences in India and beyond.
Apollo Hospitals announced that the centre will play a role in supporting clinical research in oncology. It is expected to collaborate with global institutions to bring in the right practices for cancer treatment. The emphasis on women-centric research aims to create customised therapies suited to Indian patients. In addition, the centre plans to run training programmes for oncologists and healthcare professionals as part of its long-term vision.
The centre in question, which is the first of its kind in Asia, is in line to attract patients from neighbouring countries. Medical tourism may thrive as the number of patients travelling from other countries for higher-quality specialised treatment continues to climb. This fully supports India’s regional leadership in oncology care functionality and presents partnership opportunities with the governments and NGOs that serve women’s health.
Also read: Jindal Steel in talks to acquire Thyssenkrupp Steel Europe unit
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading